Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [4]. Core Insights - The company achieved a revenue of 2.45 billion RMB in 2025, representing a year-over-year growth of 102.5%, with an adjusted net profit of 401 million RMB, also showing a significant increase of 100.13% [1]. - The product matrix continues to improve, with the core product, essence oil, generating 1.024 billion RMB in revenue, a year-over-year increase of 128.68% [2]. - The company is focusing on a "1+4+N" product strategy to ensure sustainable growth, leveraging the success of its essence oil and expanding its product offerings [2]. - Offline store performance remains strong, with direct store revenue reaching 515 million RMB, a year-over-year increase of 29.21%, while online sales surged to 1.57 billion RMB, up 147.26% [3]. - The gross margin for 2025 was reported at 82.01%, with an adjusted net profit margin of 16.36%, reflecting slight decreases from the previous year [4]. Summary by Sections Financial Performance - In 2025, the company reported total revenue of 2.45 billion RMB, with projections for 2026, 2027, and 2028 at 3.39 billion RMB, 4.53 billion RMB, and 5.79 billion RMB respectively, indicating growth rates of 38.3%, 33.6%, and 28.0% [6]. - The adjusted net profit for 2025 was 360 million RMB, with forecasts of 572 million RMB, 802 million RMB, and 1.044 billion RMB for the following years, showing growth rates of 58.8%, 40.2%, and 30.2% [6]. Product and Market Strategy - The company is enhancing its product matrix with a focus on essence oil, which has shown rapid growth, and is introducing new products like the "light white umbrella" sunscreen, which integrates multiple benefits [2]. - The company plans to deepen its presence in both high-tier and lower-tier cities, aiming to capture the upgrading consumption demand in these markets [3]. Channel Performance - The offline channel generated 5.15 billion RMB in revenue, while the online direct sales reached 1.57 billion RMB, driven by significant growth on platforms like Douyin [3]. - The company is implementing a comprehensive omnichannel strategy to enhance brand visibility and sales performance across various platforms [3].

Investment Rating - The report maintains a "Buy" rating for the company, with a current price of HKD 68.40 and a target value of HKD 91.95 [4]. Core Insights - The company has demonstrated significant revenue growth, achieving RMB 2.45 billion in revenue for 2025, a year-on-year increase of 103%, and a net profit of RMB 360 million, up 93% [9]. - The company is focusing on high-end product strategies and a multi-channel approach to enhance sales, with notable growth in both offline and online channels [9]. - The forecast for 2026 indicates a net profit of RMB 576 million, corresponding to a price-to-earnings ratio (P/E) of 15 times [9]. Financial Performance Summary - Revenue projections for the company are as follows: - 2024: RMB 1.21 billion - 2025: RMB 2.45 billion - 2026: RMB 3.58 billion - 2027: RMB 4.88 billion - 2028: RMB 6.34 billion - The growth rates for these years are projected at 50.3%, 102.5%, 45.9%, 36.6%, and 29.9% respectively [2]. - The EBITDA is expected to grow from RMB 297 million in 2024 to RMB 1.31 billion in 2028, with corresponding growth rates of 46.4% to 33.4% [2]. - The return on equity (ROE) is projected to be 30.5% in 2024, decreasing to 26.2% by 2028 [2]. Sales Channel Performance - Offline sales reached RMB 724 million in 2025, a 47% increase, while online sales surged to RMB 1.72 billion, marking a 141% increase [9]. - The company has expanded its store count to 580, with an average revenue of RMB 1.32 million per store [9]. - The Douyin channel generated RMB 957 million in revenue, a 338% increase, while WeChat sales reached RMB 194 million, up 116% [9]. Product Strategy - The company is focusing on a product strategy of "1+4+N," emphasizing the upgrade of flagship products and expanding into four core categories [9]. - Revenue from the flagship essence oil reached RMB 1.02 billion, accounting for 42% of total revenue, with significant contributions from other categories as well [9].

Investment Rating - The investment rating for the company is "Buy (Maintain)" with a target price of 105.74 HKD [5][8]. Core Insights - The company is expected to see a significant increase in net profit attributable to shareholders, projected to grow by 91-93% [2]. - The company anticipates a doubling of revenue and net profit for 2025, with revenue expected to reach 24-24.5 billion CNY, representing a year-on-year growth of 98.3-102.5% [8]. - The company is expanding its offline store network and enhancing online channels, which is expected to drive overall operational capabilities [8]. - The introduction of new products, including a children's sunscreen, and partnerships aimed at transitioning to a "skin science company" are expected to enhance the product matrix [8]. Financial Forecasts - Revenue projections for the company are as follows: - 2023: 805 million CNY - 2024: 1,209.64 million CNY (growth of 50.27%) - 2025: 2,404.21 million CNY (growth of 98.75%) - 2026: 3,383.92 million CNY (growth of 40.75%) - 2027: 4,630.44 million CNY (growth of 36.84%) [4]. - Net profit attributable to shareholders is forecasted as: - 2023: 84.52 million CNY - 2024: 186.83 million CNY (growth of 121.06%) - 2025: 357.85 million CNY (growth of 91.53%) - 2026: 573.04 million CNY (growth of 60.14%) - 2027: 797.92 million CNY (growth of 39.24%) [4]. - The company maintains a high gross margin, projected to be around 82% over the forecast period [4]. Valuation Metrics - The company is currently valued at a P/E ratio of 115.48 for 2023, decreasing to 12.23 by 2027 [4]. - The P/B ratio is projected to decline from 20.76 in 2023 to 5.20 in 2027 [4]. - The target price of 105.74 HKD corresponds to a P/E valuation of 23 times for 2026 [8].

Investment Rating - The investment rating for the company is "Buy (Maintain)" with a target price of 105.74 HKD [5][8]. Core Insights - The company is expected to see a significant increase in net profit attributable to shareholders, projected to grow by 91-93% [2]. - The company has announced a positive earnings forecast for 2025, with revenue expected to reach 24-24.5 billion CNY, representing a year-on-year growth of 98.3-102.5% [8]. - The company plans to implement an H-share incentive plan to enhance employee motivation and align interests among shareholders, the company, and employees [8]. - The company is expanding its product matrix, including the launch of a children's sunscreen and a partnership with Meilai to transition towards a "skin science company" [8]. Financial Forecasts - Revenue is projected to grow from 805 million CNY in 2023 to 4,630.44 million CNY in 2027, with a compound annual growth rate (CAGR) of 36.84% [4]. - Net profit attributable to shareholders is expected to increase from 84.52 million CNY in 2023 to 797.92 million CNY in 2027, reflecting a CAGR of 39.24% [4]. - The company's gross margin is forecasted to remain stable around 82% over the next five years [4]. Performance Metrics - The company’s earnings per share (EPS) is projected to rise from 0.60 CNY in 2023 to 5.63 CNY in 2027 [4]. - The price-to-earnings (P/E) ratio is expected to decrease from 115.48 in 2023 to 12.23 in 2027, indicating improved valuation over time [4]. - The return on equity (ROE) is anticipated to increase from 17.98% in 2023 to 42.48% in 2027, showcasing enhanced profitability [4].

Core Viewpoint - The beauty industry is expected to maintain steady growth in 2026, driven by product innovation and the rise of domestic brands, with Douyin's beauty GMV projected to grow over 20% year-on-year in January 2026, reflecting a marginal improvement during the off-season due to brand efforts in daily sales and self-broadcasting, alongside the impact of the Spring Festival timing [1][2]. Group 1: Strong Product and Brand Momentum - Companies with strong product and brand momentum are expected to achieve high growth through new product launches and category expansions, such as Ruoyuchen, which is focusing on high-end household cleaning and health products [3]. - Beijiaojie is maintaining stable performance in oral care and is expected to benefit from the trend of AKK ingredients in its probiotic raw material business [3]. - Maogeping is positioned as a high-end brand with ongoing expansion in offline counters and online sales, anticipating rapid growth across multiple product lines [3]. - Linqingxuan is benefiting from the trend of oil-based skincare, with its flagship essence oil performing well and new products showing promise [3]. - Shangmei Co. is expanding its main brand Han Shu and sub-brands, with strong growth expected from key products [3]. Group 2: Leading Brands with Strong Asset Value - Beitanie has been actively adjusting its channel and inventory mechanisms since 2025, leading to product structure upgrades and profit recovery, with strong GMV growth in January 2026 [4]. - Proya is expected to have a clear new product strategy in 2026, launching several key products and expanding its sub-brands to drive steady growth [4]. Investment Recommendations - Companies with strong fundamentals and high growth potential recommended for increased holdings include Ruoyuchen, Beijiaojie, Maogeping, Linqingxuan, and Shangmei Co. [5]. - Companies showing signs of bottom improvement include Beitanie, Proya, Dengkang Oral, Shanghai Jahwa, and Runben Co. [5].

Investment Rating - The report assigns an "Accumulate" rating for the cosmetics industry, indicating a positive outlook for selected companies within the sector [5]. Core Insights - The beauty industry is expected to maintain steady growth in 2026, driven by product innovation and the rising trend of domestic brands. The report suggests a bottom-up selection of high-growth products and brands with strong potential, as well as companies that exhibit resilience amid product and channel changes [2][5]. Summary by Sections Industry Overview - The report highlights that the cosmetics sales during the off-peak season have shown marginal improvement. It suggests focusing on products and brands with strong growth momentum and resilience in the face of changing product and channel dynamics [2]. Key Investment Points - The report identifies two main lines of investment: 1. **High-Growth Companies**: Companies like RuYuchen, BeiJiaJie, MaoGePing, LinQingXuan, and ShangMei are expected to perform well due to strong fundamentals and product innovation [5]. 2. **Brands with Strong Asset Value**: Companies such as BeiTaiNi and PoLaiYa are anticipated to see marginal improvements following adjustments in their channels and product structures [5]. Market Performance - According to data from the National Bureau of Statistics, the retail sales of cosmetics in December 2025 grew by 8.8% year-on-year, significantly outpacing the overall retail growth of 0.9%. The annual retail sales for cosmetics in 2025 reached 465.3 billion yuan, reflecting a 5.1% year-on-year increase [5]. Company Valuations - The report provides a valuation table for key companies, indicating their earnings per share (EPS) and price-to-earnings (PE) ratios for 2025E, 2026E, and 2027E. For instance, RuYuchen has an EPS of 0.59 yuan for 2025E with a PE of 60, while BeiTaiNi has an EPS of 1.10 yuan for 2025E with a PE of 43 [7].

Core Viewpoint - The beauty industry is experiencing a surge in IPO activities, with over 41 companies aiming for public listings in 2025, while simultaneously facing challenges with 10 companies exiting the capital market [1][4]. Group 1: IPO Activities - In December, Lin Qingxuan successfully listed on the Hong Kong Stock Exchange, marking it as the first high-end domestic skincare stock in Hong Kong [1]. - Major domestic beauty brands like Naturals, Proya, and Marubi are also pursuing listings, with Proya and Marubi aiming for dual listings in both A-shares and H-shares [1]. - The IPO wave includes a diverse range of companies across the beauty supply chain, including raw material suppliers and packaging companies, with 8 companies like Vicky Technology and Jiakai Biotechnology also in the IPO race [2]. Group 2: Market Challenges - Despite the IPO enthusiasm, 10 beauty-related companies have exited the A-share or New Third Board markets, indicating a stringent selection process by capital markets [4]. - Many companies, including Naturals and Vicky Technology, have faced delays in their IPO processes, often remaining in the application or advisory stages [4]. - The third-quarter report for 2025 shows that only a few beauty companies have maintained revenue growth, with many facing significant operational pressures [5]. Group 3: Industry Dynamics - The beauty industry is characterized by a dual trend of IPO excitement and market exits, highlighting the need for companies to address issues such as heavy reliance on marketing over research and development [6]. - Companies like Naturals have reported high marketing costs, with sales and marketing expenses reaching 57% of revenue, while R&D investment has decreased significantly [6]. - The reliance on flagship products, such as Lin Qingxuan's dependence on its essence oil, poses additional challenges for sustainable growth [7].

Core Viewpoint - The beauty industry is experiencing a surge in IPO activities, with over 41 beauty-related companies aiming for IPOs in 2025, indicating a robust interest in capital markets within this sector [2][3]. Group 1: IPO Activities - In December 2024, Lin Qingxuan successfully listed on the Hong Kong Stock Exchange, marking it as the first high-end domestic skincare stock in Hong Kong [2]. - Major domestic beauty brands such as Naturals, Proya, and Marubi have initiated their IPO processes, with Proya and Marubi already listed on A-shares, aiming for a dual listing in Hong Kong [2][3]. - The IPO wave includes a diverse range of companies from the beauty supply chain, including raw material suppliers, packaging companies, and brand operators [2][3]. Group 2: Market Dynamics - Since the end of 2024, there has been a notable trend of companies exiting the capital market, with 10 beauty-related companies having withdrawn from A-shares or the New Third Board [5]. - Many companies are facing delays in their IPO processes, with some, like Naturals and Weiqi Technology, still in the application or advisory stages despite having significant revenue [5][6]. - The A-share beauty companies reported a total revenue of 27.707 billion yuan and a net profit of 3.753 billion yuan in the first three quarters of 2025, with Proya leading at 7.098 billion yuan, showing only a slight growth of 1.89% year-on-year [6]. Group 3: Challenges in the Industry - The beauty industry is grappling with challenges such as an overemphasis on marketing at the expense of research and development, as evidenced by Naturals' marketing costs significantly outweighing its R&D investments [7][8]. - Companies like Lin Qingxuan are heavily reliant on a single product category for revenue, which poses risks to their long-term growth and stability [8]. - The current market environment is increasingly selective, favoring companies with solid market foundations, clear brand positioning, and strong technological barriers [5][7].

Core Insights - The beauty industry is experiencing a surge in IPO activity, with over 41 beauty-related companies aiming for IPOs since 2025, covering various segments of the supply chain [1][2] - The trend of companies seeking to become the "first stock" in their respective niches is prominent, with several brands targeting specific categories such as whitening and anti-hair loss [3] - Despite the IPO enthusiasm, there are challenges as 10 beauty-related companies have exited the capital market, indicating a stricter selection process by investors [4] IPO Activity - Numerous companies are preparing for IPOs, with notable brands like Gu Yu, Lin Qingxuan, and Plant Doctor submitting applications in 2025 [2][3] - The IPO wave includes not only brand companies but also raw material suppliers and packaging companies, indicating a comprehensive industry interest [2] - Specific milestones include Lin Qingxuan becoming the first high-end domestic skincare stock in Hong Kong and other brands aiming for dual listings [1][2] Financial Performance - In the first three quarters of 2025, eight listed beauty companies reported a total revenue of 27.707 billion yuan and a net profit of 3.753 billion yuan [5] - The leading company, Proya, achieved a revenue of 7.098 billion yuan, showing only a slight year-on-year increase of 1.89%, while Shanghai Jahwa reported a 10.83% growth [5] Industry Challenges - The beauty industry faces significant challenges, including a heavy reliance on marketing over research and development, which could hinder long-term growth [6][7] - Companies like Natural Hall and Lin Qingxuan have shown a concerning trend of low R&D investment compared to their marketing expenditures, with R&D costs declining as a percentage of revenue [6][7] - The industry's dependency on flagship products poses risks, as seen with Lin Qingxuan's reliance on its essence oil for revenue [7]

Core Viewpoint - The article provides an overview of recent IPO activities across Hong Kong, the US, and A-shares, highlighting several companies preparing for their public listings and their respective market positions. Group 1: Muxi Integrated Circuit - Muxi Integrated Circuit (Shanghai) Co., Ltd. officially listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 17, 2025, with the stock code "688802" [3] - Founded in 2020, Muxi is a leading domestic high-performance general-purpose GPU product company, focusing on the research, design, and sales of GPUs for AI training, inference, general computing, and graphics rendering [3] - Muxi's GPU products have achieved cumulative sales of over 25,000 units by the end of March 2025, with a revenue compound growth rate of 4074.52% over the past three years, and revenue of 915 million yuan in the first half of this year [5] Group 2: Woan Robotics - Woan Robotics (Shenzhen) Co., Ltd. plans to officially list on the Hong Kong Stock Exchange on December 30, 2025, with the stock code "6600" [7] - The company aims to become the "first stock of AI-embodied household robots," with an IPO market valuation between 14 billion and 18 billion HKD, raising up to 1.8 billion HKD [8] - Woan Robotics is recognized as the only company globally to comprehensively layout AI-embodied household robot systems, holding an 11.9% market share in the sector by 2024 [10] Group 3: Xunce Technology - Xunce Technology plans to list on the Hong Kong Stock Exchange on December 30, 2025, with the stock code "3317," marking it as the first company in China's AI data sector to complete an IPO [12] - The company aims to raise up to 1.2375 billion HKD through its IPO, with a focus on real-time data infrastructure and analysis solutions [12] - Xunce Technology's real-time data solutions are noted for their speed and consistency, optimizing business efficiency and flexibility [14] Group 4: InSilico Medicine - InSilico Medicine plans to list on the Hong Kong Stock Exchange on December 30, 2025, with the stock code "3696," aiming to raise up to 2.3 billion HKD [16] - The company is recognized as the largest biotech IPO in Hong Kong this year, with a focus on AI-driven drug development across various industries [17] - InSilico's core asset, Rentosertib, is a first-in-class candidate drug for idiopathic pulmonary fibrosis, showcasing the company's innovative capabilities [18] Group 5: Linqingxuan - Linqingxuan Cosmetics Group plans to list on the Hong Kong Stock Exchange on December 30, 2025, with the stock code "2657," aiming to raise over 1 billion HKD [21] - The company is positioned as the leading high-end domestic skincare brand in China, with a complete product matrix in anti-wrinkle and firming skincare [22] - Linqingxuan ranks first among all domestic high-end skincare brands in China by retail revenue in 2024 [22] Group 6: 51WORLD - 51WORLD plans to list on the Hong Kong Stock Exchange on December 30, 2025, with the stock code "6651," aiming to become the "first stock of Physical AI" [24] - The company has established a comprehensive technology capability in Physical AI, with products applied in various industries globally [24] - 51WORLD's revenue has shown significant growth, with a 63.6% increase in the first half of this year compared to the same period last year [26] Group 7: Qingsong Health Group - Qingsong Health Group plans to list on the Hong Kong Stock Exchange on December 23, 2025, with the stock code "2661," aiming to raise over 600 million HKD [28] - The company operates as a one-stop digital health and insurance service platform, covering various health-related services [28] - Qingsong Health Group's revenue has grown significantly, with an 84.7% increase in the first half of this year compared to the previous year [29] Group 8: Biran Technology - Biran Technology has passed the hearing for its listing on the Hong Kong Stock Exchange, focusing on general intelligent computing solutions [31] - The company has shown strong growth potential, with significant sales agreements in place and a focus on AI data centers and telecommunications [32] Group 9: Zhipu Technology - Zhipu Technology has passed the hearing for its listing on the Hong Kong Stock Exchange, aiming to become the "first stock of global large models" [35] - The company has achieved significant revenue growth, with a compound annual growth rate of 130% from 2022 to 2024 [36] Group 10: Tiandu Intelligent Chip - Tiandu Intelligent Chip has passed the hearing for its listing on the Hong Kong Stock Exchange, focusing on general-purpose GPU chips [38] - The company has seen a significant increase in customer numbers and product shipments, reflecting strong market recognition [39]